AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ARECOR THERAPEUTICS PLC

AGM Information Jun 9, 2023

7494_dva_2023-06-09_6d4284e9-d759-4d9e-ba55-ceb5abceee4f.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information /*<![CDATA[*/ /**/ /**/ /**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;line-height:107%;font-size:24.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h2{margin-top:18.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:107%;font-size:18.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h3{margin-top:14.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:107%;font-size:14.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h5{margin-top:11.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h6{margin-top:10.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:10.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .ae{size:595.0pt 842.0pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ae{}p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:center;line-height:normal}span.ar{color:black}p.au{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:center;line-height:150%}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;layout-grid-mode:char}span.ao{font-size:12.0pt; color:black}p.aw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;border:none}span.ax{font-style: italic}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:center} p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}table.az{margin-left:-5.4pt;border-collapse:collapse}td.ai{width:251.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;layout-grid-mode:char}td.ah{width:244.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .ae{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/

RNS Number : 2856C

Arecor Therapeutics PLC

09 June 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

RESULT OF AGM

Cambridge, UK, 9 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 9.30 am, all resolutions were duly passed.

-ENDS-

For more information, please contact:

Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060

Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060

Email: [email protected]
Mo Noonan, Communications Tel: +44 (0) 7876 444977

Email: [email protected]
Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)
Tel: +44 (0) 20 7886 2500
Consilium Strategic Communications

Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700

Email: [email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSEFFUEDSELM

Talk to a Data Expert

Have a question? We'll get back to you promptly.